Lexicon Pharmaceuticals (LXRX) Total Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Total Current Liabilities for 17 consecutive years, with $9.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 91.06% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (down 91.06% YoY), while the FY2025 annual figure was $20.9 million, down 53.88% from the prior year.
• Total Current Liabilities eased to $9.9 million in Q1 2026 per LXRX's latest filing, from $20.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $110.7 million in Q1 2025 and bottomed at $9.9 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $30.5 million across 5 years, with a median of $23.4 million in 2024.
• Annual changes were most pronounced in 2025 — Total Current Liabilities jumped 373.07% — and 2026, when it slumped 91.06%.
• Lexicon Pharmaceuticals' Total Current Liabilities stood at $23.2 million in 2022, then jumped by 36.14% to $31.5 million in 2023, then jumped by 43.43% to $45.2 million in 2024, then sank by 53.88% to $20.9 million in 2025, then plunged by 52.57% to $9.9 million in 2026.
• Business Quant data shows LXRX's Total Current Liabilities at $9.9 million in Q1 2026, $20.9 million in Q4 2025, and $21.7 million in Q3 2025.